At its July 2017 meeting, the PBAC recommended that the Pharmaceutical Benefits Scheme (PBS) listing for goserelin (Zoladex) be expanded so that all premenopausal women undergoing chemotherapy which may negatively impact their fertility can access goserelin through the PBS.
BCNA has welcomed the PBAC’s recommendation, which will need to be accepted by the Health Minister before the PBS listing can be amended.
Submission to PBAC in support of goserelin (Zoladex) for premenopausal women
Breast Cancer Network Australia (BCNA) has made a submission to the Pharmaceutical Benefits Advisory Committee* (PBAC) in support of an application by the Medical Oncology Group of Australia (MOGA) which would enable young women with hormone receptor negative early breast cancer to access the drug goserelin (Zoladex) at a subsidised cost through the Pharmaceutical Benefits Scheme (PBS).
In 2015, goserelin was added to the PBS as a treatment for premenopausal women with hormone receptor positive early breast cancer.
The research with goserelin found that it may also be helpful for fertility preservation and that this effect was found in women with both hormone receptor positive and hormone receptor negative early breast cancer undergoing chemotherapy.
MOGA made an application to PBAC to extend the current listing for goserelin to include young women with hormone receptor negative early breast cancer so that they could access goserelin through the PBS as a fertility preservation treatment. Currently, these young women have to pay approximately $330 per month if they wish to receive treatment with goserelin during chemotherapy. This cost has meant that not all women who may benefit from goserelin have been able to access it.
*The PBAC is the independent body that reviews new drugs and makes recommendations on which should be subsidised by the Australian Government through the PBS.